GENFF (Genflow Biosciences) Shares Buyback Ratio %: -41.13 (As of Aug. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genflow Biosciences Shares Buyback Ratio %?

Genflow Biosciences GENFF -0.01% Shares Buyback Ratio % is -41.13 as of Aug. 29, 2026. The stock has 1 warning sign investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Genflow Biosciences's current shares buyback ratio was -41.13%.

Genflow Biosciences Shares Buyback Ratio % Related Terms

Genflow Biosciences Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Genflow Biosciences's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genflow Biosciences Shares Buyback Ratio % Chart

Genflow Biosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Shares Buyback Ratio %
0.00 -19.60 0.00 -19.56 -41.13

Genflow Biosciences Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -19.56 0.00 -29.69 -8.82

Genflow Biosciences Shares Buyback Ratio % Calculation

Genflow Biosciences's Shares Buyback Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2024 ) - Shares Outstanding (EOP) (A: Dec. 2025 )) / Shares Outstanding (EOP) (A: Dec. 2024 )
=(349.707 - 493.548) / 349.707
=-41.13%

Genflow Biosciences's Shares Buyback Ratio for the quarter that ended in Dec. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jun. 2025 ) - Shares Outstanding (EOP) (A: Dec. 2025 )) / Shares Outstanding (EOP) (A: Jun. 2025 )
=(453.548 - 493.548) / 453.548
=-8.82%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -41.13 mean?
Genflow Biosciences (GENFF) has a Shares Buyback Ratio % of -41.13 as of Aug. 29, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Genflow Biosciences and its competitors.
Is Genflow Biosciences' Shares Buyback Ratio % too high?
Genflow Biosciences' current Shares Buyback Ratio % is -41.13.
How does Genflow Biosciences' Shares Buyback Ratio % compare to VRTX and REGN?
Genflow Biosciences' Shares Buyback Ratio % of -41.13 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Genflow Biosciences and its competitors. Genflow Biosciences's current Shares Buyback Ratio % is -41.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genflow Biosciences stock overvalued right now?
Genflow Biosciences (GENFF) has a current Shares Buyback Ratio % of -41.13. The current Shares Buyback Ratio % is -41.13. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Genflow Biosciences (GENFF), the current Shares Buyback Ratio % is -41.13 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genflow Biosciences Business Description

Other Exchanges GENF:UKWQ5:Germany
Address 6 Heddon Street, London, GBR, W1B 4BT
Genflow Biosciences PLC is a preclinical biotechnology company focused on the development of biological interventions (namely gene therapies) which are aimed at tackling the effects of aging, potentially slowing or halting the aging process and so reducing the incidence of age-related diseases and thereby increasing health span. Its flagship compound, GF-1002, is based on the delivery of a variant of the SIRT6 gene and is currently in preclinical development.